Skip to main content
Clinical Trials/NCT01934114
NCT01934114
Terminated
Not Applicable

NIR (Near Infrared Spectral Tomography)Hypoxia Imaging of Breast Tumor Response to Neoadjuvant Chemotherapy in Vivo.

Dartmouth-Hitchcock Medical Center1 site in 1 country8 target enrollmentAugust 2010
ConditionsBreast Cancer

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Breast Cancer
Sponsor
Dartmouth-Hitchcock Medical Center
Enrollment
8
Locations
1
Primary Endpoint
Quantify tumor oxygenation response in patients imaged.Determine capability of imaging dynamic to capture oxygenation changes within the tumor.
Status
Terminated
Last Updated
10 years ago

Overview

Brief Summary

The purpose of this study is to determine whether an experimental alternative imaging method, Near Infrared Spectroscopy (abbreviated as NIR), can be used with a controlled respiratory system to examine the breasts for cancer. The NIR system uses light beams to produce an image or picture of the inside of the breast. The respiratory system will help researchers get more information about the breast tissue by changing the amount of oxygen the tissue receives during NIR imaging.

Registry
clinicaltrials.gov
Start Date
August 2010
End Date
September 2015
Last Updated
10 years ago
Study Type
Observational
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • NORMAL cohort
  • Breast size and epithelial integrity adequate to allow NIR imaging exams
  • No serious associated psychiatric illnesses
  • Female, ≥25 and \<76 years old
  • Written informed consent
  • UNDER TREATMENT cohort
  • Locally advanced breast cancer, with or without metastatic disease, defined as being clinically appropriate for neoadjuvant therapy
  • Breast size and epithelial integrity adequate to allow NIR imaging exams
  • No serious associated psychiatric illnesses
  • Female, ≥25 and \<76 years old

Exclusion Criteria

  • both cohorts
  • Pre-existing respiratory conditions:
  • severe chronic obstructive pulmonary disease (including chronic bronchitis and/or emphysema)
  • Other respiratory or lung conditions which would place the patient at risk
  • presence of any other significant cardiac or pulmonary symptoms, such as moderate or severe dyspnea on exertion, orthopnea, or paroxysmal nocturnal dyspnea
  • Congestive heart failure
  • Intolerance of hyperoxia or hypercarbia as delivered by the RespirAct breathing circuit

Outcomes

Primary Outcomes

Quantify tumor oxygenation response in patients imaged.Determine capability of imaging dynamic to capture oxygenation changes within the tumor.

Time Frame: 18 weeks approximately

Analyze captured data from use of dynamic NIR topographic oximetry (in a cohort of women receiving conventional anthracycline/taxane based adjuvant chemotherapy).Quantify pathological and clinical outcomes.

Study Sites (1)

Loading locations...

Similar Trials